Free Trial
→ You cannot escape this reality (From Porter & Company) (Ad)tc pixel
NASDAQ:KZIA

Novogen 11/7/2025 Earnings Report

Novogen logo
$13.90 +0.24 (+1.76%)
As of 08:04 AM Eastern
ProfileEarnings HistoryForecast

Novogen EPS Results

Actual EPS
-$6.14
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Novogen Revenue Results

Actual Revenue
$0.59 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Novogen Announcement Details

Quarter
Date
11/7/2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Novogen Earnings Headlines

Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer
 |  prnewswire.comhttps://www.prnewswire.com/news-releases/kazia-therapeutics-expands-ongoing-phase-1b-trial-of-paxalisib-in-advanced-breast-cancer-302781345.html
Kazia Therapeutics: Diverse Cancer Pipeline Still Needs A Major Catalyst
April 30, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4895704-kazia-therapeutics-diverse-cancer-pipeline-still-needs-a-major-catalyst
The SpaceX filing is public. The window is closing.
SpaceX just filed its S-1. The IPO is confirmed for June 12 - $75 billion, ticker SPCX, potentially the largest in history. The 21-bank syndicate has already locked up shares, so retail investors won't get access. But the S-1 exposed one publicly traded company Musk cannot operate without - and it's still cheap. Dylan Jovine is releasing the ticker free before June 12 changes the price.tc pixel
May 26 at 1:00 AM  |  Behind the Markets (Ad)
Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform
April 15, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kazia-therapeutics-strengthens-scientific-leadership-with-appointment-of-dr-sudha-rao-as-chief-scientific-officer-to-lead-next-generation-oncology-platform-302742491.html
Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform
April 13, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kazia-therapeutics-expands-oncology-platform-with-first-in-class-setdb1-inhibitor-drug-development-platform-302740954.html
Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)
January 30, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kazia-therapeutics-announces-compelling-preclinical-and-translational-data-for-nuclear-pd-l1-degrader-ndl2-302674710.html
See More Novogen Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Novogen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Novogen and other key companies, straight to your email.

About Novogen

Novogen (NASDAQ:KZIA) (NASDAQ:KZIA) is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapeutics for the treatment of cancer. The company’s pipeline includes GDC-0084, a brain-penetrant phosphoinositide 3-kinase (PI3K) inhibitor in Phase II development for glioblastoma, as well as Cantrixil, an orally bioavailable small molecule designed to target treatment-resistant ovarian cancer stem cells. Novogen’s research efforts leverage structure-based drug design to optimize selectivity and pharmacokinetic profiles, seeking to address high-unmet medical needs in oncology.

Founded in Australia and now headquartered in New York City, Novogen maintains research facilities in Perth and collaborates with academic institutions and contract research organizations worldwide. The company benefits from strategic partnerships and licensing arrangements designed to advance its lead programs through clinical trials while expanding its preclinical pipeline into additional tumor types. Novogen’s global footprint enables access to diverse patient populations and fosters collaborations in neuroscience and oncology research.

Under the leadership of Chief Executive Officer Dr. Daniel Goldstein, Novogen continues to prioritize the rapid development of its clinical candidates through regulatory milestones. The management team combines expertise in medicinal chemistry, clinical development, and regulatory affairs to streamline translational research and engage with key opinion leaders. Through ongoing clinical trials and data readouts, Novogen aims to demonstrate the safety and efficacy of its novel small molecule therapies and to establish strategic partnerships for commercialization.

View Novogen Profile
Earnings Tools